1inch: Trading volume to reach $21.4 billion in 2025, BNB Chain transaction volume grows nearly 10 times year-on-year
According to Odaily, 1inch released its 2025 data review, stating that the platform completed approximately $214 billion in token swap trading volume throughout the year, a 39% year-on-year increase, with about 114 million transactions executed, more than double the previous year. In terms of network distribution, Ethereum remains the main trading hub for 1inch, with an annual trading volume of about $97.1 billion; BNB Chain recorded a trading volume of about $82.1 billion, nearly a tenfold year-on-year increase; Arbitrum and Base recorded approximately $13.2 billion and $8.8 billion in trading volume, respectively.
In addition, 1inch stated that cross-chain trading demand saw a significant rise in 2025, with an annual cross-chain swap volume of about $697 million, completing 148,000 transactions, and nearly 48,000 users utilizing the related features. Ethereum remains the core node for cross-chain liquidity, with major flows including Ethereum→BNB, BNB→Ethereum, and Ethereum→Arbitrum. 1inch pointed out that trading activity is further concentrating on core networks, while newly integrated networks have also begun to gradually contribute to trading volume.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Forex Today: US flash Consumer Sentiment and Canadian jobs in the limelight
Malaysian Ringgit: Fiscal anchor case – MUFG
Nasdaq Drops Over 300 Points After OpenAI's Revenue Comes In $20 Billion Short
BUZZ-Revolution Medicines stock drops due to concerns over pancreatic cancer drug data
On October 8, Revolution Medicines (RVMD.O) shares fell 8.1% in afternoon trading to $185.91. RBC Capital Markets stated that the share price decline appeared to be driven by the latest U.S. Food and Drug Administration (FDA) review documents regarding the company's pancreatic cancer drug Rasonque, particularly the disclosure of objective response rate data for specific RAS mutation subgroups. RBC pointed out that overall survival, rather than objective response rate, is a more meaningful indicator of efficacy, and that the sell-off overlooked Rasonque's broad activity across a variety of RAS mutation subgroups. RBC stated: "While we acknowledge that today's share price decline takes place against the backdrop of overall weakness in the biotech sector, we still believe that the market's reaction to the FDA review documents is an overreaction, given that the drug was approved on the basis of highly clinically meaningful efficacy and has received positive feedback from physicians." Including intraday fluctuations, the stock has more than doubled year-to-date. (Note: For the convenience of non-English speakers, Reuters has automatically translated its reports into several other languages. Automated translations may be inaccurate or lack necessary context; Reuters does not guarantee the accuracy of these automated translations and provides them only for reader convenience. Reuters does not accept liability for any damage or loss arising from the use of automated translation features.)
Crypto prices
More
